1
|
Oro-Ayude M, González-Sixto B, Sanmartin-Jiménez O, Garcés JR, Rodríguez-Prieto MA, Ruiz-Salas V, de Eusebio-Murillo E, Miñano-Medrano R, Escutia-Muñoz B, Feal Cortizas C, Artola-Igarza JL, Alfaro-Rubio A, Redondo P, Delgado-Jiménez Y, Sánchez-Schmidt JM, Allende-Markixana I, Alonso-Pacheco ML, García-Bracamonte B, de la Cueva-Dobao P, Navarro-Tejedor R, Ciudad-Blanco C, Carnero-González L, Vázquez-Veiga H, Cano-Martínez N, Vilarrasa-Rull E, Sánchez-Sambucety P, López-Estebaranz JL, Botella-Estrada R, Martorell-Calatayud A, Gil P, Morales-Gordillo V, Toll-Abelló A, Ocerin-Guerra I, Mayor-Arenal M, Suárez-Fernández R, Sainz-Gaspar L, Descalzo MA, Garcia-Doval I, Flórez Á. Mohs surgery: a long-term, nationwide prospective cohort to describe recurrence rate and risk factors (REGESMOHS, Spanish Registry of Mohs Surgery). J Eur Acad Dermatol Venereol 2021; 36:e35-e37. [PMID: 34374137 DOI: 10.1111/jdv.17597] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2021] [Revised: 07/21/2021] [Accepted: 07/29/2021] [Indexed: 11/29/2022]
Affiliation(s)
- M Oro-Ayude
- Complexo Universitario Hospitalario Pontevedra, Pontevedra, Spain
| | - B González-Sixto
- Complexo Universitario Hospitalario Pontevedra, Pontevedra, Spain
| | | | - J R Garcés
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Centro Médico Teknon, Barcelona, Spain
| | | | - V Ruiz-Salas
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Centro Médico Teknon, Barcelona, Spain
| | | | | | | | - C Feal Cortizas
- Complexo Universitario Hospitalario Pontevedra, Pontevedra, Spain
| | | | | | - P Redondo
- Clínica Universidad de Navarra, Pamplona, Spain
| | - Y Delgado-Jiménez
- Hospital Universitario Quirón Salud, Madrid, Spain.,Hospital Universitario de la Princesa, Madrid, Spain
| | | | | | | | | | | | | | - C Ciudad-Blanco
- Hospital General Universitario Gregorio Marañón, Madrid, Spain.,Hospital La Zarzuela, Madrid, Spain
| | | | - H Vázquez-Veiga
- Complexo Hospitalario Universitario de Santiago, Santiago Compostela, Spain
| | - N Cano-Martínez
- Hospital Infanta Leonor, Madrid, Spain.,Hospital La Zarzuela, Madrid, Spain
| | - E Vilarrasa-Rull
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.,Centro Médico Teknon, Barcelona, Spain
| | | | | | | | | | - P Gil
- Clínica Universidad de Navarra, Pamplona, Spain
| | | | | | | | | | | | - L Sainz-Gaspar
- Complexo Hospitalario Universitario de Santiago, Santiago Compostela, Spain
| | - M A Descalzo
- Fundación Piel Sana Academia Española de Dermatología, Madrid, Spain
| | - I Garcia-Doval
- Fundación Piel Sana Academia Española de Dermatología, Madrid, Spain
| | - Á Flórez
- Complexo Universitario Hospitalario Pontevedra, Pontevedra, Spain
| | | |
Collapse
|
2
|
Ruiz-Salas V, Marron M, Urbano Alcaraz M, Garcés JR, Puig L. Pinch grafting: a unique application? J Wound Care 2021; 30:504-505. [PMID: 34121435 DOI: 10.12968/jowc.2021.30.6.504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Veronica Ruiz-Salas
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - M Marron
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - M Urbano Alcaraz
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - J R Garcés
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - L Puig
- Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| |
Collapse
|
3
|
Ruiz-Salas V, Garcés JR, Miñano Medrano R, Alonso-Alonso T, Rodríguez-Prieto MÁ, López-Estebaranz JL, Sanmartín-Jiménez O, Guillén Barona C, Delgado Jiménez Y, Toll-Abelló A, Vargas Diez E, Ciudad Blanco C, Alfaro Rubio A, Allende Markixana I, de Eusebio Murillo E, Manubens-Mercadé E, Vázquez-Veiga H, Barchino Ortiz L, García-Doval I, Redondo Bellón P. Description of Patients Undergoing Mohs Surgery in Spain: Initial Report on Data From the Spanish Registry of Mohs Surgery (REGESMOHS). Actas Dermosifiliogr 2015; 106:562-8. [PMID: 26028578 DOI: 10.1016/j.ad.2015.04.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Revised: 04/02/2015] [Accepted: 04/07/2015] [Indexed: 10/23/2022] Open
Abstract
INTRODUCTION The Spanish registry of Mohs micrographic surgery started collecting data in July 2013. The aim of the registry is to report on the use of this technique in Spain and the outcomes achieved. In the present article, we describe the characteristics of patients and the tumors treated. MATERIAL AND METHODS This is a prospective cohort study of patients treated with Mohs micrographic surgery. The participating centers are hospitals where at least one intervention of this type is performed each week. All patients considered for Mohs micrographic surgery in participating centers are included in the registry except those who have been declared legally incompetent. RESULTS Between July 2013 and October 2014, data from 655 patients were included in the registry. The most common tumor involved was basal cell carcinoma, and the most common histological subtype was infiltrative basal cell carcinoma. Most of the tumors treated were located on the face or scalp, and the most common site was the nose. Almost 40% of the tumors treated were recurrent or persistent, and preoperative tumor size was similar to that reported in other European studies and in Australia. In total, 45.5% of patients had received previous surgical treatment. CONCLUSION The findings are similar to those reported in other studies, and the data collected are useful for assessing whether the results of studies carried out elsewhere are applicable in Spain.
Collapse
Affiliation(s)
- V Ruiz-Salas
- Hospital de la Santa Creu i Sant Pau, Barcelona, España.
| | - J R Garcés
- Hospital de la Santa Creu i Sant Pau, Barcelona, España; Hospital Quirón Teknon, Barcelona, España
| | - R Miñano Medrano
- Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España
| | | | | | | | | | | | - Y Delgado Jiménez
- Clínica Quirón, Madrid, España; Hospital de La Princesa, Madrid, España
| | | | | | - C Ciudad Blanco
- Hospital La Zarzuela, Madrid, España; Hospital Gregorio Marañón, Madrid, España
| | | | | | | | | | - H Vázquez-Veiga
- Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, España
| | - L Barchino Ortiz
- Hospital La Zarzuela, Madrid, España; Hospital Gregorio Marañón, Madrid, España
| | - I García-Doval
- Unidad de Investigación, Fundación Academia Española de Dermatología, Madrid, España
| | | |
Collapse
|
4
|
Ruiz-Salas V, Alegre M, López-Ferrer A, Garcés JR. Vismodegib: a review. Actas Dermosifiliogr 2013; 105:744-51. [PMID: 24359667 DOI: 10.1016/j.ad.2013.09.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2013] [Revised: 09/19/2013] [Accepted: 09/28/2013] [Indexed: 12/31/2022] Open
Abstract
In January 2012, vismodegib (Erivedge, manufactured by Genentech) became the first selective inhibitor of the Hedgehog signaling pathway to be approved by the US Food and Drug Administration for the treatment of locally advanced and metastatic basal cell carcinoma. The drug selectively binds to Smoothened, a 7-helix transmembrane receptor, thereby inhibiting activation of transcription factors of the glioma-associated oncogene family and suppressing tumor proliferation and growth. Studies published to date have assessed the efficacy of vismodegib according to clinical and radiologic outcomes but little information is available on the molecular mechanisms underpinning the proven clinical efficacy of the drug. This review will cover recent data on the Hedgehog signaling pathway and data from clinical trials with vismodegib in the treatment of basal cell carcinoma, and will consider its use in other types of tumor.
Collapse
Affiliation(s)
- V Ruiz-Salas
- Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
| | - M Alegre
- Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España
| | - A López-Ferrer
- Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España
| | - J R Garcés
- Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España
| |
Collapse
|
5
|
Abstract
Bone wax is an inert, malleable material used as a hemostatic agent in treating surgical defects. Healing by secondary intention is an appropriate approach for certain situations in dermatologic surgery. When surgical wounds are deep enough for such tissues as bone or cartilage to be exposed, dressings may adhere to granulation tissue, making removal and subsequent wound care difficult and painful. In such cases bone wax can be molded around deep tissues to create an ideal occlusive, hemostatic microenvironment that facilitates second-intention wound healing.
Collapse
Affiliation(s)
- M Alegre
- Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
| | | | | |
Collapse
|